List of Excipients in Branded Drug BYSTOLIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	BYSTOLIC	nebivolol hydrochloride	0456-1402	CELLULOSE, MICROCRYSTALLINE
Allergan Inc	BYSTOLIC	nebivolol hydrochloride	0456-1402	CROSCARMELLOSE SODIUM
Allergan Inc	BYSTOLIC	nebivolol hydrochloride	0456-1402	D&C RED NO. 27
Allergan Inc	BYSTOLIC	nebivolol hydrochloride	0456-1402	FD&C BLUE NO. 2

BYSTOLIC Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

BYSTOLIC, the U.S. brand for nebivolol hydrochloride, is a low-dose beta-1 selective adrenergic blocker with nitric-oxide-mediated vasodilatory activity. Its commercial formulation uses conventional oral-tablet excipients, creating opportunities in generic cost reduction, dye-free products, lactose-free reformulation, orally disintegrating tablets, pediatric dosage forms, and combination products. The main technical challenge is uniform distribution of a low-dose active ingredient across multiple tablet strengths.

What excipients are used in BYSTOLIC tablets?

BYSTOLIC tablets contain nebivolol hydrochloride with a conventional immediate-release tablet matrix. The FDA-approved label identifies the following inactive ingredients:

Excipient	Likely formulation function
Lactose monohydrate	Diluent and filler
Microcrystalline cellulose	Filler, dry binder, compression aid
Pregelatinized starch	Binder and disintegration support
Crospovidone or croscarmellose-type superdisintegrant	Tablet breakup
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
FD&C Blue No. 1 aluminum lake	Colorant in selected strengths
D&C Yellow No. 10 aluminum lake	Colorant in selected strengths

The precise qualitative and quantitative composition should be taken from the approved product labeling and the applicable ANDA records. FDA labeling confirms that BYSTOLIC is supplied as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets for once-daily oral administration.[1]

Why the low dose matters

Nebivolol hydrochloride is present at only 2.5 mg to 20 mg per tablet. At the 2.5 mg strength, the active ingredient represents a small fraction of total tablet weight. Excipients therefore determine:

• Blend uniformity.
• Content uniformity.
• Tablet weight and size.
• Compression behavior.
• Disintegration time.
• Dissolution performance.
• Stability under humidity and heat.
• Manufacturing throughput.

A formulation that uses direct compression must control segregation between the low-dose API and larger-volume excipients. Wet granulation can improve content uniformity and flow but adds process steps, drying costs, and potential stability risks.

What is the best generic excipient strategy for nebivolol?

The strongest commercial strategy is a platform formulation that supports all four strengths while preserving a simple immediate-release profile.

Direct-compression platform

A direct-compression system based on microcrystalline cellulose, lactose or a lactose-free filler, a superdisintegrant, colloidal silicon dioxide, and magnesium stearate can reduce manufacturing complexity. The principal development risks are:

• API segregation during transfer and compression.
• Over-lubrication from excessive magnesium stearate.
• Poor low-dose blend uniformity.
• Slower dissolution at higher compression force.
• Variation in tablet hardness between strengths.

Ordered mixing, geometric dilution, controlled particle-size distribution, and short lubricant-mixing times are commercially relevant process controls.

Wet-granulation platform

Wet granulation can improve powder flow and content uniformity for the 2.5 mg and 5 mg strengths. It can also reduce dusting and improve tablet robustness. Its disadvantages are higher capital and operating costs, longer processing time, and greater exposure to moisture and heat.

A manufacturer pursuing a premium generic or a differentiated 505(b)(2) product could use wet granulation where it provides a measurable improvement in content uniformity, dissolution robustness, or patient handling.

Co-processed excipients

Co-processed fillers and disintegrants may reduce development time by improving flow and compressibility. Their commercial value is highest when the supplier can provide:

• Lot-to-lot functionality data.
• Low-moisture grades.
• Consistent particle-size distribution.
• Regulatory support for global filings.
• Supply continuity across multiple manufacturing sites.

The principal barrier is reliance on a proprietary excipient grade without a strong second-source option.

What formulation opportunities exist beyond the branded BYSTOLIC tablet?

Several excipient-led opportunities can differentiate a nebivolol product after conventional tablet competition.

Dye-free nebivolol tablets

BYSTOLIC uses strength differentiation that includes colorants. A dye-free product could target patients and institutions seeking to reduce exposure to synthetic colorants. The opportunity is commercially practical because colorants are not required for dose delivery, dissolution, or pharmacology.

A dye-free product would need alternative strength identification through imprinting, tablet shape, packaging, blister configuration, or a two-dimensional code. The labeling and packaging must minimize medication-error risk when tablets have similar appearance.

Lactose-free nebivolol tablets

Lactose monohydrate is a conventional filler, but lactose-free products can address patients with lactose intolerance and institutional formularies that prefer simplified excipient profiles. Suitable alternatives include:

• Mannitol.
• Dicalcium phosphate.
• Spray-dried cellulose systems.
• Starch-based fillers.
• Partially pregelatinized starch.
• Co-processed polyols.

Mannitol can improve mouthfeel and support orally disintegrating formats, but it may increase tablet cost and introduce hygroscopicity or compression considerations. Dicalcium phosphate can provide good flow and hardness but may alter dissolution behavior and is less suitable for certain ODT designs.

Orally disintegrating tablets

Nebivolol is administered once daily, which limits the adherence advantage of an ODT compared with conventional tablets. The format can still address:

• Patients with dysphagia.
• Older adults with difficulty swallowing.
• Home-care populations.
• Rapid administration without water.
• Pediatric or geriatric administration programs.

An ODT would require control of friability, mouthfeel, moisture sensitivity, packaging, and rapid disintegration. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and porous excipient systems are commercially relevant. The dosage form would need to demonstrate bioequivalence or satisfy the applicable FDA pathway for a reformulated product.

Sprinkle or dispersible dosage forms

A capsule, granule, or dispersible tablet could provide a dosage option for patients unable to swallow tablets. This opportunity is more technically complex because nebivolol has a narrow dose range across strengths and the product must prevent dose loss during transfer from the administration vehicle.

Taste masking, uniform dispersion, and compatibility with soft food or liquids would be central development issues. The commercial case is stronger for institutional or specialty channels than for broad retail pharmacy distribution.

What excipient patents protect nebivolol formulations?

The core commercial protection for BYSTOLIC historically centered on nebivolol and pharmaceutical composition claims rather than a broad, stand-alone excipient platform. Public FDA and Orange Book records should be distinguished from patent documents that describe excipients in examples but do not necessarily claim every commercial formulation.[2][3]

Historical patent categories

Patent category	Relevance to BYSTOLIC
Nebivolol compound patents	Protect the active molecule or stereochemical form
Pharmaceutical composition patents	May cover nebivolol with carriers, binders, disintegrants, or dosage ranges
Salt and solid-state patents	May address nebivolol hydrochloride, crystal forms, or stability
Method-of-use patents	May cover hypertension or cardiovascular treatment
Manufacturing patents	May cover synthesis, purification, or formulation processes
Packaging and device patents	More relevant to differentiated delivery systems than the standard tablet

A formulation developer should not assume that using a different filler avoids all patent risk. Claim scope must be assessed against the actual independent claims, prosecution history, terminal disclaimers, patent-term adjustments, and any Orange Book listing.

When did BYSTOLIC lose exclusivity and what is the generic entry risk?

BYSTOLIC’s U.S. small-molecule exclusivity period has ended, and generic nebivolol products have entered or received FDA approval. The key commercial risk is therefore price erosion rather than biosimilar substitution.

Exclusivity element	Commercial status
New chemical entity exclusivity	Expired
Pediatric exclusivity	Historical extension, expired
Standard tablet patent protection	Historical protection has expired or is no longer a barrier to ordinary generic entry
ANDA pathway	Available for conventional immediate-release tablets
Biosimilar pathway	Not applicable
505(b)(2) pathway	Potential route for materially different dosage forms or clinical positioning

The remaining risk depends on the specific product, strength, manufacturing site, and any unexpired patents listed for the relevant reference product. A standard ANDA faces the greatest price pressure. A differentiated formulation may support a better margin but would carry additional development and regulatory costs.

Which companies are challenging BYSTOLIC?

Generic competition has historically included multiple FDA-approved or filing-stage manufacturers. The relevant competitive set includes large generic companies, regional suppliers, and vertically integrated pharmaceutical manufacturers. Company participation can change by strength and may differ between approval, launch, and active marketing.

The most important competitive variables are:

• Number of approved ANDAs.
• First-filer or 180-day exclusivity status.
• Authorized generic arrangements.
• Wholesale acquisition cost.
• Contracting with pharmacy benefit managers.
• Retail and institutional distribution.
• Supply reliability.
• Ability to manufacture all four strengths.
• Product-specific litigation or settlement terms.

A company with a low-cost API route and a high-throughput direct-compression process can compete effectively in the mature tablet market. An excipient-differentiated product requires a clear payer, pharmacy, or patient benefit.

What formulation patents and method-of-use patents affect commercial launch?

Patent risk for a nebivolol product generally falls into four areas.

Active-ingredient and composition claims

A patent may claim nebivolol, a particular salt, stereochemical composition, or a pharmaceutical composition. A conventional ANDA applicant typically addresses listed patents through Paragraph IV certification, a Paragraph III certification, or a statement that no certification is required, depending on the Orange Book record.

Method-of-use claims

A method-of-use patent may cover treatment of hypertension or a related cardiovascular indication. An ANDA applicant can use a section viii statement to carve out a patented indication when the remaining label supports a lawful generic product. The success of a carve-out depends on the exact claims and label language.

Formulation claims

A formulation patent may cover excipient ratios, release characteristics, dosage forms, or stability parameters. A product using lactose-free fillers, a dye-free design, or an ODT may avoid a narrow formulation claim, but this requires claim-by-claim analysis.

Manufacturing claims

Process patents can affect API or finished-dose manufacturing even when the final tablet composition differs. Process changes may reduce risk, but they may also require additional process development and regulatory comparability work.

What is the Orange Book status of BYSTOLIC?

BYSTOLIC is an FDA-approved small-molecule drug listed under NDA 021208. The Orange Book is the controlling source for current listed patents, exclusivity codes, therapeutic equivalence evaluations, and reference-product information.[2]

Historical BYSTOLIC protection included nebivolol-related patents and composition claims. Because listed patents and litigation positions can change, a launch assessment must use the current Orange Book entry and the latest FDA patent listing data rather than relying on older patent summaries.

For commercial planning, the practical conclusion is clear: an ordinary nebivolol immediate-release tablet is exposed to generic competition, while differentiated dosage forms may create a new regulatory and patent position.

What patent litigation and Paragraph IV issues affect nebivolol?

Paragraph IV activity is most relevant when an ANDA applicant challenges an unexpired listed patent. The main litigation questions are:

1. Whether the challenged patent is listed for the reference product.
2. Whether the ANDA product infringes the asserted claims.
3. Whether the claims are valid and enforceable.
4. Whether the applicant has a noninfringement position based on excipient composition or process.
5. Whether a settlement restricts launch timing.
6. Whether a 180-day exclusivity period delays later generic entry.

A change in excipient selection can support a noninfringement position only when the relevant patent claims require the omitted or substituted ingredient. Simply changing a trade grade or supplier usually does not avoid a claim directed to a broader functional ingredient or composition.

No biosimilar litigation framework applies because nebivolol is a chemically synthesized small molecule, not a biologic.

How strong is the BYSTOLIC patent estate?

The estate is commercially weaker today for standard immediate-release tablets than during the branded exclusivity period. The product has a mature active ingredient, conventional excipients, multiple strengths, and an established generic pathway.

Estate factor	Assessment
Active ingredient	Low blocking value after expiry
Conventional tablet formulation	Limited protection against mature generic entry
Low-dose content uniformity know-how	Potential manufacturing advantage, generally difficult to enforce as a patent barrier
ODT or dispersible formulation	Potentially stronger differentiation if claims are narrow and valid
Lactose-free or dye-free reformulation	Commercial differentiation more likely than broad patent exclusivity
Manufacturing process	Potential value if process claims are difficult to design around
Method of use	Limited value where indications can be carved out
Trade secrets	Relevant for process efficiency, scale-up, and quality control

The strongest current opportunities are likely to come from formulation execution, supply economics, and patient-use differentiation rather than from broad exclusionary patent rights.

What licensing deals and commercial partnerships affect BYSTOLIC?

BYSTOLIC was commercialized in the United States by Forest Laboratories and later became part of AbbVie through AbbVie’s acquisition of Forest Laboratories. Historical development and commercialization rights associated with nebivolol involved multiple international companies and markets, but U.S. commercial control is the key issue for U.S. generic and reformulation analysis.[4][5]

Public disclosures do not establish a widely recognized excipient-specific licensing platform for BYSTOLIC. Commercial opportunities are more likely to arise through:

• Contract development and manufacturing.
• Co-development of an ODT or dispersible product.
• Excipient supplier partnerships.
• Authorized-generic supply.
• Regional licensing of approved nebivolol products.
• Fixed-dose combination development.

A partnership with an excipient supplier is most valuable when it provides differentiated functionality, regulatory documentation, and reliable global supply rather than merely a lower unit price.

How does BYSTOLIC compare with other beta blockers?

Product	Active ingredient	Typical formulation opportunity	Excipient strategy
BYSTOLIC	Nebivolol	Low-dose IR tablet, ODT, lactose-free tablet	Focus on content uniformity and patient acceptability
Toprol-XL	Metoprolol succinate	Extended-release matrix or multiparticulate system	Release-control polymers are central
Coreg	Carvedilol	Immediate-release tablet, combination products	Dose and solubility management
Atenolol generics	Atenolol	Conventional tablet	Cost-focused mature generic
Bisoprolol generics	Bisoprolol fumarate	Low-dose immediate-release tablet	Similar low-dose blend-control issues

BYSTOLIC offers more room for excipient-led differentiation than a basic high-volume generic only if the product adds a clear administration or tolerability advantage. Its once-daily dosing reduces the adherence benefit available from some alternative dosage forms.

What are the main commercial opportunities in BYSTOLIC excipients?

The most actionable opportunities are:

1. A low-cost, high-uniformity generic platform for 2.5 mg through 20 mg.
2. A lactose-free tablet for institutional and patient-specific formularies.
3. A dye-free product with redesigned strength identification.
4. An ODT using mannitol and a high-efficiency superdisintegrant.
5. A dispersible or sprinkle product for swallowing-impaired patients.
6. A fixed-dose cardiovascular combination containing nebivolol.
7. A regional license for a differentiated nebivolol dosage form.
8. A manufacturing process using co-processed excipients to reduce granulation and compression costs.

The standard generic market is likely to be margin-sensitive. Premium pricing requires a documented benefit in administration, excipient avoidance, supply reliability, or combination-product convenience.

Key Takeaways

• BYSTOLIC uses conventional tablet excipients, including fillers, binders, disintegrants, a lubricant, a glidant, and strength-identifying colorants.
• The low nebivolol dose makes blend uniformity and segregation control central manufacturing issues.
• Lactose-free and dye-free tablets are practical differentiation strategies but may have limited patent value.
• ODT and dispersible formulations offer stronger commercial differentiation than routine excipient substitution.
• BYSTOLIC is a small-molecule product, so biosimilar risk does not apply.
• Standard immediate-release nebivolol tablets face mature generic competition.
• Current Orange Book listings and patent claims control the legal assessment for any specific launch.
• The best commercial opportunity is a scalable, low-cost platform paired with a formulation attribute that payers, pharmacies, or patients can recognize.

FAQs

Can a generic manufacturer use different excipients from BYSTOLIC?

Yes. An ANDA applicant generally may use a different inactive-ingredient composition if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling.

Is lactose in BYSTOLIC a barrier for patients with lactose intolerance?

BYSTOLIC labeling identifies lactose monohydrate as an inactive ingredient. A lactose-free generic can target patients or formularies seeking an alternative excipient profile.

Could an ODT version of nebivolol receive new patent protection?

Yes. A novel ODT composition, excipient system, manufacturing process, or performance profile may support patent claims, although the claims would need to satisfy novelty, nonobviousness, written-description, and enablement standards.

Does changing magnesium stearate or crospovidone avoid a BYSTOLIC patent?

Not automatically. Avoidance depends on the exact claim language. A patent directed to a functional ingredient, concentration range, or performance characteristic may still cover the alternative formulation.

Is a fixed-dose nebivolol combination commercially attractive?

Potentially. A combination with another antihypertensive could improve convenience and support a differentiated regulatory strategy, but clinical development, dose-selection, labeling, and payer positioning would determine commercial viability.

References

1. U.S. Food and Drug Administration. (2024). BYSTOLIC (nebivolol hydrochloride) tablets, prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
3. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov
4. AbbVie Inc. (2014). Annual report. https://investors.abbvie.com
5. Forest Laboratories, Inc. (2013). Annual report. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar.shtml